Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech
GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...
Cell-therapy
Blue Shield Biotech Faces Bankruptcy Proceedings After Missing Debt Payments
The Nanjing Qixia District People’s Court has accepted a bankruptcy liquidation case for Blue Shield...
IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis
China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...
Legend Biotech’s Carvykti Secures FDA Approval for Expanded Use in Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that the US Food and Drug Administration...
Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production
Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...
Novatim Immune Therapeutics’ KQ-2003 Gains Tacit Approval for POEMS Syndrome Clinical Trial in China
Novatim Immune Therapeutics (Zhejiang) Co., Ltd, a China-based specialist in cancer immunotherapy, has received tacit...
IASO Biotherapeutics Gets NMPA Go-Ahead for BCMA-Targeted CAR-T Therapy Clinical Trial
IASO Biotherapeutics, a China-based biopharmaceutical company, has announced that it has received approval from the...
Shanghai Medicilon Forms Strategic Partnerships with Binhui Biopharmaceutical and Innoforce Pharmaceuticals
Shanghai Medicilon Biomedical Co., Ltd (SHA: 688202), a prominent Chinese biotech firm, has entered into...
Sanofi Projects EUR 13 Billion in Dupixent Sales for 2024 Despite Q1 Challenges
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its guidance for the first...
OBiO Technology Partners with Saierxin Bio to Support Treg Cell Therapy Development
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a Chinese Contract Research Organization (CRO) specializing in...
iRegene’s NouvSight001 Gains Orphan Drug Designation for Retinitis Pigmentosa Treatment
Wuhan-based cell therapy innovator iRegene has secured Orphan Drug Designation (ODD) from the U.S. FDA...
Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy
Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...
Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use
GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...
Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...
Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the fourth quarter and...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point
China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...